Table 4.

Pooled treatment success among subgroups of studies with clofazimine in their regimens.

Subgroups	No. of study	Treatment success (95% CI)	Heterogeneity
			p-value	I2 (%)
Treatment regimens
Clofazimine-containing regimens	19 studies	56.8 (47.0–66.5)	0.000	100
Non-clofazimine containing regimens	21 studies	67.9 (62.0–73.8)	0.000	100
Length of treatment
≥12 Months	5 studies	58.7 (33.1–84.3)	0.000	100
<12 Months	14 studies	56.2 (46.0–66.6)	0.000	88
Type of patients
Non-HIV patients with MAC pulmonary disease	6 studies	51.0 (24.1–77.7)	0.000	100
HIV patients with disseminated MAC disease	13 studies	58.7 (48.7-69.0)	0.000	100
Number of drugs used
≤3	11 studies	64.5 (53.7–75.3)	0.000	100
>3	9 studies	47.6 (31.5–63.7)	0.000	100
Definition of cure
Culture conversion	16 studies	53.1 (42.0–64.3)	0.000	100
Symptom improvements	5 studies	71.0 (53.1–88.7)	0.000	100
Type of study
Randomized trials	12 studies	57.5 (46.6–68.4)	0.000	100
Non-randomized trials	7 studies	54.8 (37.3–72.4)	0.000	100
Year of publication
>2,000	5 studies	47.4 (19.0–75.0)	0.000	100
≤2,000	14 studies	60.2 (50.6–69.7)	0.000	100